Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-LY3871801 ADME study in healthy males
NCT06049108Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ocadusertib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3871801 Radioactivity at 7 days and Fecal Excretion of LY3871801 Radioactivity at 7 days. Started Sep 2023; status: completed.
02
Drugs
ocadusertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06049108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049108.